BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 14733599)

  • 1. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
    Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
    Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
    Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
    Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.
    Barth RF; Wu G; Yang W; Binns PJ; Riley KJ; Patel H; Coderre JA; Tjarks W; Bandyopadhyaya AK; Thirumamagal BT; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):899-903. PubMed ID: 15308165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
    Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
    Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
    Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
    Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
    Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Kawabata S; Sferra TJ; Bandyopadhyaya AK; Tjarks W; Ferketich AK; Moeschberger ML; Binns PJ; Riley KJ; Coderre JA; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2006 Jun; 12(12):3792-802. PubMed ID: 16778107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors.
    Yang W; Barth RF; Adams DM; Soloway AH
    Cancer Res; 1997 Oct; 57(19):4333-9. PubMed ID: 9331095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.
    Yang W; Barth RF; Wu G; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Binns PJ; Riley K; Patel H; Coderre JA; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):981-5. PubMed ID: 15308179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors.
    Capala J; Barth RF; Bendayan M; Lauzon M; Adams DM; Soloway AH; Fenstermaker RA; Carlsson J
    Bioconjug Chem; 1996; 7(1):7-15. PubMed ID: 8741985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
    Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
    Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
    Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.
    Yang W; Barth RF; Wu G; Huo T; Tjarks W; Ciesielski M; Fenstermaker RA; Ross BD; Wikstrand CJ; Riley KJ; Binns PJ
    J Neurooncol; 2009 Dec; 95(3):355-365. PubMed ID: 19588228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.
    Barth RF; Yang W; Al-Madhoun AS; Johnsamuel J; Byun Y; Chandra S; Smith DR; Tjarks W; Eriksson S
    Cancer Res; 2004 Sep; 64(17):6287-95. PubMed ID: 15342417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.
    Barth RF; Wu G; Meisen WH; Nakkula RJ; Yang W; Huo T; Kellough DA; Kaumaya P; Turro C; Agius LM; Kaur B
    Onco Targets Ther; 2016; 9():2769-81. PubMed ID: 27274273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of carboranyl uridines as boron delivery agents for neutron capture therapy.
    Liu L; Barth RF; Tjarks W; Soloway AH; Anisuzzaman AK
    Anticancer Res; 1996; 16(1):113-20. PubMed ID: 8615595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation.
    Barth RF; Yang W; Coderre JA
    J Neurooncol; 2003; 62(1-2):61-74. PubMed ID: 12749703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo evaluation of phosphorous-containing derivatives of dodecahydro-closo-dodecaborate for boron neutron capture therapy of gliomas and sarcomas.
    Tjarks W; Barth RF; Rotaru JH; Adams DM; Yang W; Kultyshev RG; Forrester J; Barnum BA; Soloway AH; Shore SG
    Anticancer Res; 2001; 21(2A):841-6. PubMed ID: 11396173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent.
    Matalka KZ; Barth RF; Staubus AE; Moeschberger ML; Coderre JA
    Radiat Res; 1994 Jan; 137(1):44-51. PubMed ID: 8265787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.